• Otolaryngologic involvement is rarely a manifestation of drug-induced systemic lupus erythematosus (SLE). Hoarseness developed in a 60-year-old man that was secondary to ulcerated lesions, which involved the epiglottis and arytenoepiglottic folds, with serologic evidence of SLE after he had been treated with hydralazine for six months. Histopathologic study of an epiglottic "pseudotumor" disclosed necrotizing vasculitis. To our knowledge, this is the first reported case of laryngeal involvement as a complication of hydralazine-induced SLE.
(Arch Intern Med 1984;144:2271-2272)
Weiser GA, Forouhar FA, White WB. Hydralazine Hoarseness: A New Appearance of Drug-Induced Systemic Lupus Erythematosus. Arch Intern Med. 1984;144(11):2271–2272. doi:10.1001/archinte.1984.04400020199034
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: